Total (N = 39) | |
---|---|
Index diagnosis | |
Age at cancer diagnosis, years | 7.3 (3.7–12.1) |
Age at end first pregnancy, years | 27.0 (23.0–29.0) |
Index diagnosis | |
Leukemia | 17 (43.6%) |
Lymphoma | 5 (12.8%) |
Sarcoma | 8 (20.5%) |
Aplastic anemia | 6 (15.4%) |
Homozygous beta-thalassemia | 2 (5.1%) |
Wilms’ tumor | 1 (2.6%) |
Treatment | |
Doxorubicin treatment | 29 (74.4%) |
Equivalent cumulative dosage, mg/m2 | 270 (168–356) |
Antimetabolites | 15 (38.5%) |
Alkylating agents | 35 (89.7%) |
Platinum-based agents | 4 (10.3%) |
Methotrexate | 19 (48.7%) |
Radiotherapy, any | 11 (28.2%) |
Total body irradiation | 4 (10.3) |
Thoracic radiotherapy | 7 (17.9%) |
Dosage, gray | 12 (5–36) |
Abdominal radiotherapy | 5 (12.8%) |
Brain radiotherapy | 7 (17.9%) |
Neck radiotherapy | 10 (25.6%) |
Other risk factors | |
Heart failure risk score* | 5 (4–7) |
Low risk (< 3) | 4 (10.3%) |
Medium risk (3–5) | 19 (48.7%) |
High risk (> 5) | 16 (41.0%) |
History of cardiotoxicity | 5 (12.8%) |
History of heart failure | 1 (2.6%) |
Smoking status prior to first pregnancy | |
Never smoked | 32 (82.1%) |
Stopped smoking | 6 (15.4%) |
Active smoker | 1 (2.6%) |
Family history of premature cardiovascular disease | 7 (17.9%) |
Betablocker use up to 1st trimester of 1st pregnancy | 3 (7.7%) |